Business Context and Reporting Period
This Form 8-K Current Report was filed by Athira Pharma, Inc. (not Leonabio, Inc.) on January 8, 2021. The filing primarily addresses executive compensation decisions and upcoming investor communications. The company is incorporated in Delaware and trades on The Nasdaq Global Select Market under the symbol ATHA.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to executive compensation:
- Dr. Leen Kawas (CEO): $357,000
- Ms. Glenna Mileson (CFO): $215,600
- Dr. Hans Moebius (CMO): $190,120
- Dr. Mark Litton (COO): $172,000
- Dr. Kevin Church (VP of Discovery): $57,500
Total disclosed 2020 bonus payments for these five executives amount to $992,220.
Material Changes
The filing reports the approval of 2020 bonus payments by the Compensation Committee on January 8, 2021. These payments recognize achievements in advancing product candidates and completing financing and corporate objectives during 2020. No other material financial or operational changes are detailed in the text of this report.
Guidance, Outlook, and Risks
Outlook and Communications: Management announced that starting on or after January 11, 2021, they will provide a corporate update to analysts and investors via one-on-one meetings. Presentation slides for these meetings are attached as Exhibit 99.1.
Legal Disclaimer: The information in Item 7.01 and the attached slides are furnished, not filed, and are not subject to Section 18 liabilities of the Exchange Act. They are not incorporated by reference into other filings unless expressly stated.
Risks: The filing text does not explicitly list new risk factors or contingencies beyond standard regulatory disclaimers.
Investor Verification Checklist
- Verify the company name is Athira Pharma, Inc. (the input metadata incorrectly listed Leonabio, Inc.).
- Review Exhibit 99.1 (Presentation Slides) for the detailed corporate update and product candidate progress mentioned in Item 7.01.
- Confirm the total cash outflow for the disclosed executive bonuses ($992,220) against the company's cash position in the most recent 10-K or 10-Q.
- Monitor upcoming one-on-one meetings scheduled for January 11, 2021, or later for specific guidance on financing and product development.